One-Year Outcomes After Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention: The T-TIME Randomized Trial

Saved in:
Bibliographic Details
Published inCirculation. Cardiovascular interventions Vol. 13; no. 2; p. e008855
Main Authors Maznyczka, Annette M, McCartney, Peter J, Eteiba, Hany, Greenwood, John P, Muir, Douglas F, Chowdhary, Saqib, Gershlick, Anthony H, Appleby, Clare, Cotton, James M, Wragg, Andrew, Curzen, Nick, Oldroyd, Keith G, Lindsay, Mitchell, McEntegart, Margaret, Rocchiccioli, J Paul, Shaukat, Aadil, Good, Richard, Watkins, Stuart, Robertson, Keith, Malkin, Christopher, Martin, Lynn, Gillespie, Lynsey, Weir, Robin A, Ford, Thomas J, Petrie, Mark C, Murphy, Aengus, Petrie, Colin J, Ramparsad, Nitish, Wetherall, Kirsty, Fox, Keith A, Ford, Ian, McConnachie, Alex, Berry, Colin
Format Journal Article
LanguageEnglish
Published United States American Heart Association, Inc 01.02.2020
Subjects
Aged
Coronary Artery Disease - diagnostic imaging
Coronary Artery Disease - physiopathology
Coronary Artery Disease - therapy
Double-Blind Method
Female
Fibrinolytic Agents - administration & dosage
Fibrinolytic Agents - adverse effects
Humans
Male
Middle Aged
No-Reflow Phenomenon - etiology
No-Reflow Phenomenon - physiopathology
Percutaneous Coronary Intervention - adverse effects
Prospective Studies
Risk Factors
ST Elevation Myocardial Infarction - diagnostic imaging
ST Elevation Myocardial Infarction - physiopathology
ST Elevation Myocardial Infarction - therapy
Thrombolytic Therapy - adverse effects
Time Factors
Tissue Plasminogen Activator - administration & dosage
Tissue Plasminogen Activator - adverse effects
Treatment Outcome
United Kingdom
United Kingdom
fibrinolysis
anticoagulants
Scotland
humans
prognosis
Online AccessGet full text

Cover

More Information
ISSN:1941-7640
1941-7632
DOI:10.1161/CIRCINTERVENTIONS.119.008855